Andrew D. Simmons
Exelixis (United States)(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase(1995)2,782 cited
- → Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring aBRCA1orBRCA2Gene Alteration(2020)664 cited
- → Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients(2016)655 cited
- → Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC(2013)624 cited
- → Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers(2017)576 cited
- → Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma(2017)403 cited
- → Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study(2020)385 cited
- → Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer(2018)281 cited
- → Correction: Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients(2016)245 cited
- → Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy(2022)238 cited